Stem Cell Therapy in Autism Spectrum Disorders

Phase 1WithdrawnNCT01974973

Neurogen Brain and Spine Institute

Overview

The purpose of this study was to study the effect of stem cell therapy on common symptoms in patients with autism spectrum disorders

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Autism Spectrum Disorders

Interventions

Autologous bone marrow mononuclear cell transplantationPROCEDURE

Intrathecal autologous bone marrow mononuclear cell transplantation

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed cases of any type of autism spectrum disorders * age above 6 months Exclusion Criteria: * presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[Hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia

Locations (1)

Neurogen brain and spine institute

Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

Improvement in the scales for Autism spectrum disorders

Time frame: Six months

Secondary Outcomes

Positron Emission Tomography- computed tomography to study change in brain metabolism

Time frame: six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.